에서 실시간으로 운영 중이에요! 자세히 알아보기

Pulmonx

LUNG

시가총액 US$7645만

1.78 USD

-0.07

3.78%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

1.78

0.00

0%

1일

-3.78%

5일

-1.66%

1개월

-8.72%

3개월

22.76%

6개월

21.92%

연초 이후

-22.61%

1년

13.38%

5년

-95.4%

10년

-95.47%

소개: Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

직원 수: 296

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 41.7%

중립 58.3%

부정적 0%

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:

Pulmonx to Participate in Upcoming Investor Conferences

Zacks Investment Research

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year

Zacks Investment Research

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx Q2 Earnings Call Highlights

Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.

Pulmonx Q2 Earnings Call Highlights

Zacks Investment Research

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.